[Our experience in treating patients with surface cancer of the bladder].
210 patients with surface cancer of the bladder were divided into three groups. 67 patients of group 1 underwent transurethral resection of the bladder (TRB) followed by preventive intravesical chemotherapy. 91 patients of group 2 received preventive intravesical BCG after TRB. 61 control patients (group 3) had TRB only. Recurrences emerged in 15 (16.5%), 12 (62.7%) and 45 (73.8%) group 2, 1 and 3 patients, respectively. The preventive chemotherapy was effective only in patients with primary tumor (the recurrence rate 42.3%), the relapses being less responsive to it (the recurrence rate 75.6%).
Matveev
B P
BP
Figurin
K M
KM
Romanov
V A
VA
Cheban
N L
NL
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control; D011182:Postoperative Care / Q000379:methods; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine
Nash opyt lecheniia bol'nykh poverkhnostnym rakom mochevogo puzyria.